Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ivabradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 known ✓ | Q9Y3Q4 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ivabradine SCHEMBL333201 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29687794 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29387763 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL5163239 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL333200 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL2589476 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29465192 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL1032017 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL2821678 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29561458 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4522 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12630822-B2 | Treatment of heart failure in human subjects | NOVO NORDISK A/S (DK) | 2026-05-19 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260097012-A1 | COMPOSITIONS AND METHODS FOR TREATING GRAFT-RELATED ARRHYTHMIA | BLUEROCK THERAPEUTICS LP (US) | 2026-04-09 | — | — | US | claimed |
| US-20260078161-A1 | METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS | KEROS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12569497-B2 | Use of HCN inhibitors for treatment of cancer | THE UNIVERSITY OF HONG KONG (CN) | 2026-03-10 | — | — | US | claimed |
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4678656-A1 | METHODS FOR PRODUCING ATRIOVENTRICULAR CANAL (AVC)-LIKE CARDIOMYOCYTES | Stichting Amsterdam UMC (NL) | 2026-01-14 | — | — | EP | claimed |
| EP-4666076-A1 | METHODS OF PROGNOSIS AND TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION USING URINARY PROTEIN LEVELS | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | claimed |
| US-4933179-A | IMMUNOLOGY | SYNTEX (U.S.A.) INC. (US) | 1990-06-12 | — | — | US | claimed |
| EP-0315153-A2 | Vaccine adjuvant | SYNTEX (U.S.A.) INC. (US) | 1989-05-10 | — | — | EP | claimed |
| US-4772466-A | ANTIGEN, GLYCOL ETHER-BASED SURFACTANT, IMMUNOSTIMULATING GLYCOPEPTIDE AND METABOLIZABLE NONTOXIC OIL | SYNTEX (U.S.A.) INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-4770874-A | EMULSIFYING AN ANTIGEN WITH AN IMMUNOSTIMULATING GLYCOPEPTIDE, POLYETHER BLOCK COPOLYMER, GLYCOL ETHER-BASED SURFACTANT, BUFFERED SALINE SOLUTION; VACINE | SYNTEX (U.S.A.) INC. (US) | 1988-09-13 | — | — | US | claimed |
| US-4684625-A | Method for enhancing the anti-infective activity of muramyldipeptide derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-08-04 | — | — | US | claimed |
| US-4606918-A | IMMUNOSTIMULATING GLYCOPEPTIDE; EMULSIFICATION | SYNTEX (U.S.A.) INC. (US) | 1986-08-19 | — | — | US | claimed |
| EP-0135376-A2 | Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them | SYNTEX (U.S.A.) INC. (US) | 1985-03-27 | — | — | EP | claimed |
| US-4459185-A | SURFACTANT, LEVELING AGENTS | OBATA, DONI, DAIWA, FINE CHEMICALS CO., LTD. (JP) | 1984-07-10 | — | — | US | claimed |
| US-4357322-A | ADMINISTERING MURAMYL OR DESMETHYLMURAMYL DIPEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1982-11-02 | — | — | US | claimed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | claimed |